(@panhammarstrom.bsky.social)

We engineered ultrapotent IgA antibodies, derived from cross-reactive neutralizing IgG, originally isolated from a SARS-CoV-2-vaccinated and SARS-CoV-1 convalescent donor. Still work nicely against all Omicron variants! journals.asm.org/doi/full/10....

loading . . .

Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants | Journal of Virology The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) JN.1 strain, which became globally predominant in the first half of 2024, has an additional L455S mutation in its receptor-binding domain compared to its precursor, BA.2.86, enhancing its ability to evade immune responses (1–3). Some subvariants derived from JN.1, such as KP.2 and KP.3, exhibit even greater immune escape abilities (4, 5). The reduced antibody response to JN.1 and its derivative variants is likely responsible for the increase in infections and hospitalizations in summer 2024 (6). Given concerns about immunological imprinting and the lack of an effective mucosal vaccine (7), administering cross-reactive monoclonal antibodies (mAbs) at the mucosal surface as pre-exposure prophylaxis may offer alternative protection. https://journals.asm.org/doi/full/10.1128/jvi.01740-24?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org